Post Profile






Drugs approved with limited data aren’t always well-tested later

(Reuters Health) - New medicines that win U.S. marketing approval without conclusive evidence of their effectiveness aren't always proven to work after they go on sale, a recent research review suggests.
read more

share

Related Posts


EU recommends suspending hundreds of drugs tested by Indian firm

Health : Reuters: Health

LONDON (Reuters) - Europe's medicines regulator has recommended the suspension of more than 300 generic drug approvals and drug applications due to "unreliable" tests conducted by Indian contract research firm Micro Therapeutic Rese...

Pfizer wins EU's approval for Ibrance as Novartis readies rival drug

Health : Reuters: Health

LONDON (Reuters) - U.S. drugmaker Pfizer said on Wednesday it had won approval from the European Union for its best-selling breast cancer drug Ibrance, making it the first medicine of its kind to reach the European market.

CHMP backs Novartis's Zykadia for first-line use in lung cancer

Health : Reuters: Health

ZURICH (Reuters) - Novartis's push to win approval for Zykadia as an initial treatment for a type of lung cancer got a lift on Friday with a positive recommendation from the European Medicines Agency's Committee for Medicinal Produc...

Company-funded studies of approved drugs may not catch safety issues

Health : Reuters: Health

(Reuters Health) - Studies drug companies fund after medicines go on sale may be too small to detect rare side effects, a recent German study suggests.

Second Drug Receives FDA Approval for Bladder Cancer Based on Research Led by NYU Langone

Health : Newswise Medical News

The U.S. Food and Drug Administration has granted accelerated approval to a second drug in less than a month for first-line treatment for advanced bladder cancer - again based on clinical trial findings from the same researcher from...

Comments


Copyright © 2016 Regator, LLC